Skip Navigation


QJM Advance Access originally published online on October 19, 2007
QJM 2007 100(11):737-738; doi:10.1093/qjmed/hcm091
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
100/11/737    most recent
hcm091v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Madan, A.
Right arrow Articles by Grennan, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Madan, A.
Right arrow Articles by Grennan, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Anti-CCP antibodies as an aid to prioritization of patients referred to the rheumatology clinic

The first 10% of the full text of this article appears below.

Sir,

As noted in your review article,1 anti-cyclic citrullinated peptide antibodies (CCP) have been shown to be more sensitive and specific for rheumatoid arthritis (RA) than the rheumatoid factor (RF).2 It is also well accepted that patients with early RA should be seen and treated as soon as . . . [Full Text of this Article]

A. Madan, R. Belshaw and D. Grennan

Wrightington Hospital
Wigan
UK

email: ayesha.madan@wwl.nhs.uk


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?